Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice?
Maria V DeligiorgiMihalis I PanayiotidisDimitrios T TrafalisPublished in: Expert review of clinical pharmacology (2020)
Nonclinical data have established links between RANKL signaling and breast cancer initiation and progression, rationalizing exploring the potential bone-independent anticancer role of denosumab beyond SREs prevention. Preclinical and preliminary clinical data show that denosumab may inhibit carcinogenesis in BRCA mutation carriers. Denosumab adjuvant in early breast cancer has been shown, though inconsistently, to provide a disease-free survival benefit for a subgroup of patients. Despite promising results, the incorporation of denosumab in preventive and therapeutic protocols of breast cancer beyond prevention of SREs cannot be endorsed until further research consolidates its efficacy.
Keyphrases
- bone mineral density
- giant cell
- postmenopausal women
- free survival
- electronic health record
- body composition
- clinical practice
- early breast cancer
- end stage renal disease
- big data
- ejection fraction
- newly diagnosed
- chronic kidney disease
- breast cancer risk
- early stage
- prognostic factors
- machine learning
- peritoneal dialysis
- data analysis
- clinical trial
- risk assessment
- bone marrow
- climate change
- bone loss